Roche shells out $200M for rights to Vaccibody’s neoantigen cancer vaccine

Roche’s Genentech arm is putting down $200 million in upfronts and near-term payments — and potentially $515M more down the road — for global rights to Norwegian biotech Vaccibody’s neoantigen cancer vaccine candidate. The companies are joining forces to develop Vaccibody’s personalized vaccine candidate VB10.NEO in the US and Europe. According…

Click to view original post